Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Support Care Cancer ; 29(2): 1025-1033, 2021 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-32572611

RESUMO

BACKGROUND: Esophagectomy for cancer strongly impairs quality of life. The aim of this trial was to evaluate the effect of the nutritional and respiratory counseling on postoperative quality of life. METHODS: At hospital discharge, patients were randomized into four groups receiving respectively: nutritional and respiratory counseling, nutritional counseling alone, respiratory counseling alone, or standard care. The main endpoint was the impairment in quality of life in the first month after surgery. Linear mixed effect models were estimated to assess mean score differences (MDs) in quality of life scores. RESULTS: Patients receiving nutritional counseling reported less appetite loss (MD - 17.7, 95% CI - 32.2 to -3.3) than those not receiving nutritional counseling at 1 month after surgery. Dyspnea was similar between patients receiving vs. those not receiving respiratory counseling (MD - 3.1, 95% CI - 10.8 to 4.6). Global quality of life was clinically similar between patients receiving vs. those not receiving nutritional counseling over time (MD 0.9, 95% CI - 5.5 to 7.3), as well as in patients receiving vs. those not receiving respiratory counseling over time (MD 0.7, 95% CI - 5.9 to 7.2). CONCLUSIONS: Intensive postoperative care does not affect global quality of life even if nutritional counseling reduced appetite loss.


Assuntos
Aconselhamento/métodos , Neoplasias Esofágicas/dietoterapia , Neoplasias Esofágicas/cirurgia , Esofagectomia/métodos , Terapia Nutricional/métodos , Qualidade de Vida/psicologia , Respiração/efeitos dos fármacos , Idoso , Feminino , Educação em Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Inquéritos e Questionários
2.
Int J Cancer ; 119(4): 735-40, 2006 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-16550605

RESUMO

About 3-4% of cirrhotic patients develop primary liver cancer every year. Specific serologic markers have not yet been identified for screening of high risk patients. The serpin squamous cell carcinoma antigen (SCCA) is overexpressed in liver cancer and circulating SCCA-IgM complexes have been described in patients with hepatocellular carcinoma (HCC). The aim of the present study was to assess the behavior of SCCA-IgM in relation to HCC development in patients with cirrhosis. A retrospective, longitudinal study was conducted in a cohort of prospectively followed cirrhotic patients. Two groups with similar clinical profile at presentation were studied : group A included 16 patients who developed HCC during a median follow up of 4 years; group B included 17 patients who did not develop HCC during the same time interval. Circulating SCCA-IgM immune complexes were determined using a recently standardized ELISA assay. At presentation similar levels of SCCA-IgM complexes [mean +/- SD: 267.40 +/- 382.25 U/ml vs. 249.10 +/- 446.90 U/ml, p = 0.9006] and of alpha-fetoprotein [AFP; 24.11 +/- 59.04 IU/ml vs. 10.91 +/- 23.34 IU/ml, p = 0.3995] were detected in group A and in group B. The increase over time (phi) of SCCA-IgM, assessed within at least one year before clinical diagnosis of HCC, was remarkably higher in group A than in group B (mean +/- SD = 280.05 +/- 606.71 (U/ml)/year vs. -37.92 +/- 95.94 (U/ml)/year, p = 0.0408), while AFP increase was not significantly different (11.89 +/- 23.27 (IU/ml)/year vs. 3.67 +/- 11.46 (IU/ml)/year, p = 0.2179). Receiver operating characteristic (ROC) curves were plotted for the rate of change in the levels of both markers and the diagnostic accuracy measured as AUROC was higher for SCCA-IgM phi (0.821) than for AFP phi (0.654). In conclusion, the progressive increase of SCCA-IgM over time was associated with liver tumor development, suggesting that monitoring the behavior of SCCA-IgM might become useful to identify cirrhotic patients at higher risk of HCC development.


Assuntos
Complexo Antígeno-Anticorpo/imunologia , Antígenos de Neoplasias/imunologia , Carcinoma Hepatocelular/complicações , Carcinoma Hepatocelular/imunologia , Imunoglobulina M/imunologia , Cirrose Hepática/complicações , Cirrose Hepática/imunologia , Serpinas/imunologia , Idoso , Antígenos de Neoplasias/metabolismo , Carcinoma Hepatocelular/metabolismo , Progressão da Doença , Feminino , Seguimentos , Humanos , Cirrose Hepática/metabolismo , Masculino , Pessoa de Meia-Idade , Serpinas/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA